DOCSLIB.ORG

Adjuvant EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Still an Investigational Approach

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Adjuvant EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Still an Investigational Approach 390 Editorial Commentary Adjuvant EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: still an investigational approach Jacek Jassem Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland Correspondence to: Jacek Jassem. Department of Oncology and Radiotherapy, Medical University of Gdańsk, 7 Dębinki St. 80-211, Gdańsk, Poland. Email: [email protected]. Provenance: This is an invited article commissioned by the Academic Editor Dr. Zhizhou Yang (Washington University School of Medicine, St. Louis, MO, USA). Comment on: Pennell NA, Neal JW, Chaft JE, et al. SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. J Clin Oncol 2019;37:97-104. Submitted Aug 18, 2019. Accepted for publication Aug 30, 2019. doi: 10.21037/tlcr.2019.09.02 View this article at: http://dx.doi.org/10.21037/tlcr.2019.09.02 The development of epidermal growth factor receptor astonishing activity in advanced disease (6). Just 3 more tyrosine kinase inhibitors (EGFR-TKIs) have revolutionized years were needed to establish the optimal 3-year duration treatment paradigms in lung cancer. Currently, EGFR of adjuvant treatment (7). Similarly, only 3 years elapsed TKIs constitute first- and second-line treatment of from the first trial showing the efficacy of dabrafenib plus choice for EGFR-mutant advanced non-small cell lung trametinib, drugs that target the mitogen-activated protein cancer (NSCLC) patients. The first-generation TKIs kinase (MAPK) pathway in advanced malignant melanoma (gefitinib, erlotinib and icotinib) have been supplemented with BRAF V600 mutations (8), to the demonstration of by second (afatinib and dacomitinib) and third-generation their benefit in adjuvant treatment (9). (osimertinib) molecules. Several other EGFR-TKIs are At present, the only standard systemic adjuvant treatment currently being investigated in clinical trials (1). option in operable stage II-III NSCLC, regardless of EGFR Typically, targeted anti-cancer therapies in solid mutation status, is cytotoxic chemotherapy, despite its mere malignancies are first investigated in advanced stages, and 5-year overall survival (OS) gain of 5% (10). subsequently agents with confirmed activity are promptly Until now only five randomized studies have been submitted to studies in early disease. An example of performed to assess EGFR-TKIs in operable NSCLC such development includes trastuzumab, a monoclonal (Table 1). Two of these studies compared EGFR TKI vs. antibody used in human type 2 EGFR (HER2) positive placebo (11,12), one chemotherapy followed by EGFR breast cancer. The first phase 3 study reporting the high TKI vs. chemotherapy alone (13), and two EGFR TKI efficacy of this agent in metastatic disease was published in vs. chemotherapy (14,15). The results of two early studies 2001 (2), and just 4 years later three large randomized trials including molecularly unselected patients were negative. demonstrated its value in the adjuvant setting (3,4). Adjuvant The prematurely closed NCIC CTG BR19 study did studies using trastuzumab in breast cancer included not show disease-free survival (DFS) or OS benefit of an impressive total number of around 20,000 patients, gefitinib for 2 years compared to placebo (11). Similarly, no and resulted in widespread implementation of this superiority was found from adjuvant erlotinib vs. placebo compound in the preoperative and postoperative settings. in the RADIANT study (12), which included patients with Another spectacular example is imatinib, a TKI used in EGFR protein-positive tumors by immunohistochemistry gastrointestinal stromal tumor, a relatively rare malignancy. or with EGFR amplification by fluorescence in situ, the Efficacy of this compound in an adjuvant setting (5) was biomarkers currently considered ineffective in selection for documented 7 years after the first report showing its EGFR TKIs. © Translational lung cancer research. All rights reserved. Transl Lung Cancer Res 2019;8(Suppl 4):S387-S390 | http://dx.doi.org/10.21037/tlcr.2019.09.02 S388 Jassem. EGFR TKIs in early NSCLC Table 1 Completed randomized studies of postoperative therapy with EGFR TKIs in NSCLC Selection N N Primary Study Phase Stage Region Study arms Main results (mEGFR) criteria (total) (mEGFR) endpoint North BR19 (11) III All NSCLC IBIIIA 503 15 G vs. placebo (2 y) OS NR America EGFR+ by OS NR; median DFS RADIANT (12) III IBIIIA Global 973 161 E vs. placebo (2 y) OS IHC or FISH 46.4 vs. 28.5 m (NS) PC × 4 with vs. Median DFS 39.8 vs. Li et al. (13) II mEGFR IIIA (N2) China 60 60 DFS without G (6 m) 27.0 (P=0.014) Two-year DFS rate 81% EVAN (14) II mEGFR IIIA China 102 102 E (2 y) vs. 4 × PV DFS vs. 54% (P=0.01) ADJUVANT (15) III mEGFR II–IIIA China 222 222 G (2 y) vs. 4 × PV DFS Median DFS 28.7 vs. (N1–N2) 18.0 m (P=0.005) EGFR TKI, epidermal growth factor receptor tyrosine kinase inhibitor; NSCLC, non-small cell lung cancer; mEGFR, patients with EGFR mutation; G, gefitinib; OS, overall survival; NR, not reported; IHC, immunochemistry; FISH, fluorescence in situ hybridization; E, erlotinib; DFS, disease free survival; NS, not significant; PC, pemetrexed plus cisplatin; PV, cisplatin plus vinorelbine. As expected, more promising were the results of three was not reached, the 5-year DFS was 56% (95% CI: 45– completed studies (all performed in China), enrolling 66%), and the 5-year OS was 86% (95% CI: 77–92%). selected patients with EGFR-mutant tumors. The first of Disease recurred in 40 patients, including four while on them, a small phase 2 trial, showed significantly longer adjuvant erlotinib. Treatment adherence was relatively poor, DFS of gefitinib for 6 months following pemetrexed- with 40% of patients requiring dose reductions by 50%, carboplatin combination, compared with chemotherapy and 16% further reduction to 25% of the original dose. Of alone (13). Another randomized phase 2 study (EVAN) the 36 patients with recurrence after completing erlotinib showed significantly higher 2-year DFS of erlotinib for treatment, 26 were retreated with this compound, and the 2 years compared to four cycles of cisplatin-vinorelbine majority of them derived clinical benefit from re-exposure. chemotherapy (14). The only phase 3 study (ADJUVANT) Interestingly, of the 20 patients who had determined showed significantly longer DFS of gefitinib for 2 years EGFR mutation status of the recurrent tumor, all but one compared to four cycles of a cisplatin-vinorelbine maintained the original canonical EGFR mutation pattern. combination, but general results were disappointingly grim, The only patient with acquired T790M resistance mutation with almost all patients relapsing within 4 years (15). The was among those four who developed progression while meta-analysis of the five above-mentioned randomized receiving adjuvant erlotinib. This may imply the hypothesis studies (including only patients with EGFR mutation) that EGFR TKIs inhibit rather than kill cancer cells, and showed increased DFS with EGFR-TKI-based regimens that prolonged anti-EGFR treatment is unlikely to induce (HR 0.52; 95% CI: 0.34–0.78, P=0.002), but this was not resistance mechanisms. The SELECT study was properly translated into OS benefit (16). designed and executed and provides another signal for Most recently presented were the results of an open-label potential role of EGFR TKI in adjuvant setting. However, single-arm phase 2 study (SELECT) performed in the USA, due to all the limitations of single-arm design, it still does that investigated the efficacy of adjuvant erlotinib in patients not provide strong evidence. with EGFR-mutant early-stage NSCLC (17). Considering In view of the relatively high incidence of EGFR-mutant the scarcity of data on adjuvant EGFR TKIs in the non- NSCLC, the number of studies investigating the role of Asian populations, this study has raised great interest. The EGFR TKI in an adjuvant setting, and the total number of SELECT study included 100 stage IA–IIIA patients and was participating patients is strikingly low. It is really difficult powered to demonstrate a 2-year DFS greater than 86%, to explain the reluctance to carry out more trials addressing i.e., 10% more compared with the historic figure of 76%. this concept. Additionally, the quality of randomized studies After a median follow-up of 5.2 years, this primary endpoint performed so far has been relatively low in terms of patient was met: 2-year DFS was 88%. The median DFS and OS selection, study design and execution. All three randomized © Translational lung cancer research. All rights reserved. Transl Lung Cancer Res 2019;8(Suppl 4):S387-S390 | http://dx.doi.org/10.21037/tlcr.2019.09.02 Translational Lung Cancer Research, Vol 8, Suppl 4 December 2019 S389 studies enrolling exclusively EGFR-mutated patients were constituting a common resistance mechanism. Osimertinib, small and included the Chinese population. Patients from a third-generation EGFR TKI, has a minimal inhibition East Asia comprise a higher proportion of EGFR-mutant of wild-type EGFR, resulting in lower toxicity (18). This cases than those from other geographical regions, and compound is also more potent, and has a strong affinity for have distinctive clinicopathologic features. Hence, there sensitizing and resistance T790M mutation (19). is the question of whether the results of these studies may The role of EGFR TKIs in an adjuvant setting is be generalized, even though 83% of the SELECT study the subject of a few ongoing clinical studies. In the subjects were of non-Asian ethnicity. ALCHEMIST-EGFR (NCT02193282) trial, initiated in Importantly, none of the completed studies in patients 2014, EGFR-mutant NSCLC patients are randomized selected by EGFR mutation used OS as the primary to 2-year erlotinib or placebo, both preceded by adjuvant endpoint.
Load more

Recommended publications
  • The Predictive Values of Advanced Non-Small Cell Lung
    ORIGINAL RESEARCH published: 26 August 2021 doi: 10.3389/fonc.2021.646577 The Predictive Values of Advanced Non-Small Cell Lung Cancer Patients Harboring Uncommon EGFR Mutations—The Mutation Patterns, Use of Different Generations of EGFR-TKIs, and Concurrent Edited by: Genetic Alterations Francois X. Claret, University of Texas MD Anderson † † Cancer Center, United States Jiarong Tan , Chengping Hu , Pengbo Deng*, Rongjun Wan, Liming Cao, Min Li, Reviewed by: Huaping Yang, Qihua Gu, Jian An and Juan Jiang Lin Liu, Department of Respiratory Medicine, Xiangya Hospital of Central South University, Changsha, China Nankai University, China Hui Guo, First Affiliated Hospital of Xi’an Introduction: Epidermal growth factor receptor (EGFR) 19del and L858R mutation are Jiaotong University, China “ ” Tony Y. Hu, known as common mutations in non-small cell lung cancer (NSCLC) and predict Tulane University, United States sensitivities to EGFR tyrosine kinase inhibitors (TKIs), whereas 20ins and T790M *Correspondence: mutations confer drug-resistance to EGFR-TKIs. The role of the remaining uncommon Pengbo Deng EGFR mutations remains elusive. [email protected] †These authors have contributed Methods: We retrospectively screened a group of NSCLC patients with uncommon equally to this work EGFR mutations other than 20ins and T790M. The mutation patterns, use of different generations of EGFR-TKIs, and concurrent genetic alterations were analyzed. Meanwhile, Specialty section: This article was submitted to a cohort of patients with single 19del or L858R were included for comparison. Cancer Molecular Targets Results: A total of 180/1,300 (13.8%) patients were identified. There were 102 patients and Therapeutics, a section of the journal with advanced or recurrent NSCLC that received first-line therapy of gefitinib/erlotinib/ Frontiers in Oncology icotinib and afatinib and were eligible for analysis.
    [Show full text]
  • Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies
    Int. J. Mol. Sci. 2014, 15, 13768-13801; doi:10.3390/ijms150813768 OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Review Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies Mohammad Hojjat-Farsangi Department of Oncology-Pathology, Immune and Gene Therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna and Karolinska Institute, Stockholm 17176, Sweden; E-Mail: [email protected]; Tel.: +46-517-74308; Fax: +46-517-75897 Received: 3 July 2014; in revised form: 31 July 2014 / Accepted: 5 August 2014 / Published: 8 August 2014 Abstract: Chemotherapeutic and cytotoxic drugs are widely used in the treatment of cancer. In spite of the improvements in the life quality of patients, their effectiveness is compromised by several disadvantages. This represents a demand for developing new effective strategies with focusing on tumor cells and minimum side effects. Targeted cancer therapies and personalized medicine have been defined as a new type of emerging treatments. Small molecule inhibitors (SMIs) are among the most effective drugs for targeted cancer therapy. The growing number of approved SMIs of receptor tyrosine kinases (RTKs) i.e., tyrosine kinase inhibitors (TKIs) in the clinical oncology imply the increasing attention and application of these therapeutic tools. Most of the current approved RTK–TKIs in preclinical and clinical settings are multi-targeted inhibitors with several side effects. Only a few specific/selective RTK–TKIs have been developed for the treatment of cancer patients. Specific/selective RTK–TKIs have shown less deleterious effects compared to multi-targeted inhibitors.
    [Show full text]
  • Efficacy and Influence Factors of Icotinib Hydrochloride in Treating Advanced Non-Small Cell Lung Cancer
    European Review for Medical and Pharmacological Sciences 2017; 21: 266-274 Efficacy and influence factors of icotinib hydrochloride in treating advanced non-small cell lung cancer X.-H. MA, T.-D. TIAN, H.-M. LIU, Q.-J. LI, Q.-L. GAO, L. LI, B. SHI Integrated TCM & Western Medicine Department, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China Abstract. – OBJECTIVE: To evaluate the effi- Introduction cacy and safety of icotinib hydrochloride in the treatment of patients with advanced non-small In the most parts of the world, the lung cancer cell lung cancer (NSCLC) and discuss the influ- ranks on the top list between global tumor occur- ence factors on efficacy. rence and mortality, which seriously threatens PATIENTS AND METHODS: 120 treatment-ex- the human health and life. Lung cancer mainly perienced patients confirmed by pathology or includes non-small cell lung cancer (NSCLC) cytology with stage III B-IV non-small cell lung cancer took icotinib hydrochloride and erlotinib and small cell lung cancer (SCLC), in which orally until the occurrence of disease progres- NSCLC accounts for 80% and has a five-year 1,2 sion or serious adverse reactions. Then, the effi- survival rate of only 12-15% . Due to the oc- cacy of icotinib hydrochloride and the related in- cult features of lung cancer at the early stages, fluence factors were analyzed. over 70% patients with lung cancer have missed RESULTS: In icotinib hydrochloride group, the the chance of surgery when they felt ill. More- response rate and the disease control rate were over, less than 1/3 NSCLC patients are early 30.00% and 65.00%, and the median progres- sion-free survival time was 179 days (95% CI: diagnosed and subjected to excision.
    [Show full text]
  • Targeted/Immunotherapy & Molecular Profiling – State-Of-The-Art in Cancer
    Targeted/Immunotherapy & Molecular Profiling – State-of-the-art in Cancer Care Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland Clinic 1 Outline • Role of Molecular Profiling in the management of brain metastases • Targeted/Immunotherapy in Management of brain metastases • Management of brain metastases in the coming 3–5 years 2 Epidemiology of brain metastases Primary tumor Relative prevalence of brain metastases* Colon: 5% Annual US incidence: >170K Ratio mets/primary: 10:1 All cancer patients: 15%–30% Melanoma: 9% Autopsy incidence: 10%–30% Mean age: 60 years Unknown primary: 11% Median survival: 4–6 months Other known primary: 13% Breast: 15% Lung: 48% *Incidence increasing with better systemic Rx and improved survival Courtesy: John Suh. Wen PY, et al. In: DeVita VT Jr, et al, eds. 3 Cancer: Principles & Practice of Oncology. 2001:2656-2670. Incidence of brain metastasis is increasing Incidence of brain metastasis is increasing1: • Improvements in imaging (e.g. MRI) • Clinical trial screening • Improvements in systemic cancer control (brain is a sanctuary site) • Rates of brain metastasis may be influenced by Brain metastases may be changing treatments underdiagnosed • Autopsy results reveal brain – 25% of lung cancer patients have brain metastasis at initial metastases that were not presentation diagnosed clinically2 • Clinical trial screening reveals – 80% of lung cancer patients patients with asymptomatic surviving >2 years will develop brain metastases1 brain metastases 1. Ba JL et al. Oncology 2015; 29: 250-257; 2. Ahluwalia MS, Winkler F. ASCO 2015: MRI, magnetic resonance imaging. http://meetinglibrary.asco.org/content/115000067-156.
    [Show full text]
  • Tyrosine Kinase Inhibitors for Solid Tumors in the Past 20 Years (2001–2020) Liling Huang†, Shiyu Jiang† and Yuankai Shi*
    Huang et al. J Hematol Oncol (2020) 13:143 https://doi.org/10.1186/s13045-020-00977-0 REVIEW Open Access Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020) Liling Huang†, Shiyu Jiang† and Yuankai Shi* Abstract Tyrosine kinases are implicated in tumorigenesis and progression, and have emerged as major targets for drug discovery. Tyrosine kinase inhibitors (TKIs) inhibit corresponding kinases from phosphorylating tyrosine residues of their substrates and then block the activation of downstream signaling pathways. Over the past 20 years, multiple robust and well-tolerated TKIs with single or multiple targets including EGFR, ALK, ROS1, HER2, NTRK, VEGFR, RET, MET, MEK, FGFR, PDGFR, and KIT have been developed, contributing to the realization of precision cancer medicine based on individual patient’s genetic alteration features. TKIs have dramatically improved patients’ survival and quality of life, and shifted treatment paradigm of various solid tumors. In this article, we summarized the developing history of TKIs for treatment of solid tumors, aiming to provide up-to-date evidence for clinical decision-making and insight for future studies. Keywords: Tyrosine kinase inhibitors, Solid tumors, Targeted therapy Introduction activation of tyrosine kinases due to mutations, translo- According to GLOBOCAN 2018, an estimated 18.1 cations, or amplifcations is implicated in tumorigenesis, million new cancer cases and 9.6 million cancer deaths progression, invasion, and metastasis of malignancies. occurred in 2018 worldwide [1]. Targeted agents are In addition, wild-type tyrosine kinases can also func- superior to traditional chemotherapeutic ones in selec- tion as critical nodes for pathway activation in cancer.
    [Show full text]
  • Lncrna APCDD1L-AS1 Induces Icotinib Resistance by Inhibition Of
    Wu et al. Biomarker Research (2021) 9:9 https://doi.org/10.1186/s40364-021-00262-3 RESEARCH Open Access LncRNA APCDD1L-AS1 induces icotinib resistance by inhibition of EGFR autophagic degradation via the miR-1322/miR-1972/ miR-324-3p-SIRT5 axis in lung adenocarcinoma Jie Wu1,2†, Chunlei Zheng3,4,5†, Yizhe Wang1, Zichang Yang3,4,5,CeLi3,4,5, Wanxia Fang3,4,5, Yue Jin3,4,5, Kezuo Hou3,4,5, Yang Cheng1, Jianfei Qi6, Xiujuan Qu3,4,5, Yunpeng Liu3,4,5, Xiaofang Che3,4,5* and Xuejun Hu1* Abstract Background: Epidermal growth factor receptor-tyrosinase kinase inhibitor (EGFR-TKI) resistance is the major obstacle in the treatment of lung adenocarcinoma (LUAD) patients harboring EGFR-sensitive mutations. However, the long non-coding RNAs (lncRNAs) related to EGFR-TKIs resistance and their functional mechanisms are still largely unknown. This study aimed to investigate the role and regulatory mechanism of lncRNA APCDD1L-AS1 in icotinib resistance of lung cancer. Methods: Molecular approaches including qRT-PCR, MTT assay, colony formation, RNA interference and cell transfection, RNA immunoprecipitation (RIP), dual luciferase reporter assay, RNA fluorescence in situ hybridization, TUNEL assay, flow cytometry, immunoblotting, xenograft model and transcriptome sequencing were used to investigate the mechanism of APCDD1L-AS1 in icotinib resistance. Results: A novel lncRNA, APCDD1L-AS1 was identified as the most significantly upregulated lncRNA in icotinib- resistant LUAD cells by the transcriptome sequencing and differential lncRNA expression analysis. We found that APCDD1L-AS1 not only promoted icotinib resistance, but also upregulated the protein expression level of EGFR. Mechanistically, APCDD1L-AS1 promoted icotinib resistance and EGFR upregulation by sponging with miR-1322/ miR-1972/miR-324-3p to remove the transcription inhibition of SIRT5.
    [Show full text]
  • Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
    cancers Review Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy 1,2, 3,4 1 2 3, Charles Pottier * , Margaux Fresnais , Marie Gilon , Guy Jérusalem ,Rémi Longuespée y 1, and Nor Eddine Sounni y 1 Laboratory of Tumor and Development Biology, GIGA-Cancer and GIGA-I3, GIGA-Research, University Hospital of Liège, 4000 Liège, Belgium; [email protected] (M.G.); [email protected] (N.E.S.) 2 Department of Medical Oncology, University Hospital of Liège, 4000 Liège, Belgium; [email protected] 3 Department of Clinical Pharmacology and Pharmacoepidemiology, University Hospital of Heidelberg, 69120 Heidelberg, Germany; [email protected] (M.F.); [email protected] (R.L.) 4 German Cancer Consortium (DKTK)-German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany * Correspondence: [email protected] Equivalent contribution. y Received: 17 January 2020; Accepted: 16 March 2020; Published: 20 March 2020 Abstract: Receptor tyrosine kinases (RTKs) are key regulatory signaling proteins governing cancer cell growth and metastasis. During the last two decades, several molecules targeting RTKs were used in oncology as a first or second line therapy in different types of cancer. However, their effectiveness is limited by the appearance of resistance or adverse effects. In this review, we summarize the main features of RTKs and their inhibitors (RTKIs), their current use in oncology, and mechanisms of resistance. We also describe the technological advances of artificial intelligence, chemoproteomics, and microfluidics in elaborating powerful strategies that could be used in providing more efficient and selective small molecules inhibitors of RTKs.
    [Show full text]
  • Effects of Icotinib, a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer
    2066 ONCOLOGY REPORTS 27: 2066-2072, 2012 Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer GUANGDIE YANG*, YINAN YAO, JIANYA ZHOU and QIONG ZHAO* Department of Respiratory Disease, The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou 310003, Zhejiang, P.R. China Received January 11, 2012; Accepted February 13, 2012 DOI: 10.3892/or.2012.1741 Abstract. Epidermal growth factor receptor (EGFR) is one treated with surgery, radiation and chemotherapy (2). The use of the most promising targets for non-small cell lung cancer of targeted therapies is increasing as the survival advantage for (NSCLC). Our study demonstrated the antitumor effects of adjuvant chemotherapy is less than 5% with increased toxicity icotinib hydrochloride, a highly selective epidermal growth (3,4). Although chemotherapy has been the standard of care for factor receptor tyrosine kinase inhibitor (EGFR TKI), in two NSCLC patients, current clinical efforts are directed at targeted EGFR-mutated lung cancer cell lines compared to A549, a cell agents to improve outcome and reduce toxicity (5). The most line without EGFR mutations. We incubated PC-9 and HCC827 common targeted agents that are being used in the treatment human lung cancer cell lines both with (E746-A750) mutations of NSLC include those that target key components in cancer with various concentrations of icotinib and gefitinib for 48 h. cell signaling, such as the vascular endothelial growth factor Cell proliferation and migration were determined using a real- receptor (VEGFR), platelet-derived growth factor receptor time cell invasion and migration assay and cytotoxicity assay.
    [Show full text]
  • Hand-Foot Syndrome in a Patient with Metastatic Lung Adenocarcinoma Induced by High-Dose Icotinib: a Case Report and Review of the Literature
    ONCOLOGY LETTERS 4: 1341-1343, 2012 Hand-foot syndrome in a patient with metastatic lung adenocarcinoma induced by high-dose icotinib: A case report and review of the literature YULONG ZHENG, WEIJIA FANG and NONG XU Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, P.R. China Received April 18, 2012; Accepted July 27, 2012 DOI: 10.3892/ol.2012.904 Abstract. Icotinib is a new oral epidermal growth factor cytarabine, docetaxel and capecitabine (5), as well as certain tyrosine kinase inhibitor (EGFR-TKI). The most frequent oral targeted therapies such as sunitinib and sorafenib (6). side-effects of icotinib include rash and diarrhea. Hand-foot HFS induced by EGFR-TKI is uncommon and has been only syndrome (HFS) induced by EGFR-TKI is rare. The present sporadically reported in the literature (7-9). We report a case study describes, for the first time, HFS induced by high‑dose of HFS caused by high-dose icotinib, which, to the best of our icotinib in a 65-year old female with metastatic lung adeno- knowledge, has not been previously described. carcinoma. The patient developed HFS during the first week of icotinib treatment with characteristic clinical presentation. Case report HFS regressed after icotinib dose-reduction was initiated. HFS may occur with icotinib, especially when administered A 65-year old female (non-smoker) with metastatic lung in high doses. adenocarcinoma received one cycle of intravenous chemo- therapy with pemetrexed (500 mg/m2, on day 1) plus cisplatin Introduction (25 mg/m2, on days 1-3). The patient experienced serious vomiting (NCI-CTC 3.0, grade 3) and refused to continue.
    [Show full text]
  • A Marked Response to Icotinib in a Patient with Large Cell Neuroendocrine Carcinoma Harboring an EGFR Mutation: a Case Report
    ONCOLOGY LETTERS 10: 1575-1578, 2015 A marked response to icotinib in a patient with large cell neuroendocrine carcinoma harboring an EGFR mutation: A case report YUEHONG WANG, YI HONG SHEN, SHANNI MA and JIANYING ZHOU Department of Respiratory Disease, The First Affiliated Hospital of the College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China Received September 7, 2014; Accepted May 29, 2015 DOI: 10.3892/ol.2015.3405 Abstract. The present study reports the case of an 84-year-old evidence has indicated that LCNEC shares numerous morpho- male with primary pulmonary large cell neuroendocrine logical, immunohistochemical and molecular characteristics carcinoma (LCNEC) harboring an epidermal growth factor with small cell lung cancer (SCLC), as well as treatment receptor (EGFR) gene mutation that exhibited a long-lasting strategies and a poor prognosis (1). The optimal treatment response to the EGFR-tyrosine kinase inhibitor (EGFR-TKI) regime for patients with LCNEC has yet to be established. icotinib. The patient had an extensive smoking history, a poor Recently, the use of epidermal growth factor receptor-tyrosine performance status, and presented with an irregular mass in the kinase inhibitors (EGFR-TKIs) has been demonstrated to be middle lobe of the right lung on computed tomography (CT) an effective therapeutic strategy for patients with non-SCLC and an enlarged left supraclavicular lymph node on physical (NSCLC), particularly for those with EGFR mutations (2,3). examination. Right middle lobe bronchial brushing during However, EGFR mutations typically occur in patients with fiberoptic bronchoscopyidentified poorly‑differentiated cancer adenocarcinoma and investigations of EGFR mutations in cells.
    [Show full text]
  • And Second-Generation Tkis—There Is Still Place for Them in EGFR-Mutant NSCLC Patients
    47 Review Article EGFR first- and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients Niki Karachaliou1,2, Manuel Fernandez-Bruno1, Jillian Wilhelmina Paulina Bracht2, Rafael Rosell2,3,4,5 1QuironSalud Group, Institute of Oncology Rosell (IOR), University Hospital Sagrat Cor, Barcelona, Spain; 2Pangaea Oncology, Laboratory of Molecular Biology, Quiron-Dexeus University Institute, Barcelona, Spain; 3Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain; 4Institute of Oncology Rosell (IOR), Quiron-Dexeus University Institute, Barcelona, Spain; 5Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain Contributions: (I) Conception and design: N Karachaliou, R Rosell; (II) Administrative support: All authors; (III) Provision of study materials or patients: N Karachaliou, M Fernandez-Bruno; (IV) Collection and assembly of data: N Karachaliou, M Fernandez-Bruno, JW Bracht; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Rafael Rosell. Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain; Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain. Email: [email protected]; Niki Karachaliou. QuironSalud Group, Institute of Oncology Rosell (IOR), University Hospital Sagrat Cor, Barcelona, Spain. Email: [email protected]. Abstract: Identification of epidermal growth factor receptor (EGFR) as a molecular target has radically changed the treatment of metastatic non-small cell lung cancer (NSCLC) from standard chemotherapy to personalized, targeted therapy. First-, second- and third-generation EGFR tyrosine kinase inhibitors (TKIs) are now available for the treatment of EGFR-mutant NSCLC patients. This review will focus on the clinical development of first- and second-generation EGFR TKIs.
    [Show full text]
  • Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer
    pharmaceuticals Review Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer Kyu Sic You 1,2,† , Yong Weon Yi 3,† , Jeonghee Cho 3 , Jeong-Soo Park 1,* and Yeon-Sun Seong 1,2,3,* 1 Department of Biochemistry, College of Medicine, Dankook University, Cheonan 31116, Chungcheongnam-do, Korea; [email protected] 2 Graduate School of Convergence Medical Science, Dankook University, Cheonan 3116, Chungcheongnam-do, Korea 3 Department of Nanobiomedical Science, Dankook University, Cheonan 31116, Chungcheongnam-do, Korea; [email protected] (Y.W.Y.); [email protected] (J.C.) * Correspondence: [email protected] (J.-S.P.); [email protected] (Y.-S.S.); Tel.: +82-41-550-3876 (J.-S.P.); +82-41-550-3875 (Y.-S.S.) † These authors contributed equally to this work. Abstract: Triple-negative breast cancer (TNBC) is a subset of breast cancer with aggressive charac- teristics and few therapeutic options. The lack of an appropriate therapeutic target is a challenging issue in treating TNBC. Although a high level expression of epidermal growth factor receptor (EGFR) has been associated with a poor prognosis among patients with TNBC, targeted anti-EGFR therapies have demonstrated limited efficacy for TNBC treatment in both clinical and preclinical settings. However, with the advantage of a number of clinically approved EGFR inhibitors (EGFRis), combi- nation strategies have been explored as a promising approach to overcome the intrinsic resistance of TNBC to EGFRis. In this review, we analyzed the literature on the combination of EGFRis with Citation: You, K.S.; Yi, Y.W.; Cho, J.; other molecularly targeted therapeutics or conventional chemotherapeutics to understand the current Park, J.-S.; Seong, Y.-S.
    [Show full text]